VTGN Jan 2025 10.000 call
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 10.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 531 |
Business WireVistagen to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in New York City.
Business WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2 deve
Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New York City.
